OncoTherapy Science, Inc.

2026/11/20 20:23 Updated
Market Cap: $35.8M (¥5.7B)
Stock Price: $0.09 (¥14)
Exchange Rate: 1 USD = ¥159.74

Notice Regarding Setting Record Date for Extraordinary General Meeting of Shareholders, Convening of Extraordinary General Meeting of Shareholders and Reduction of Capital

A gratuitous capital reduction is planned to reduce capital from 335,654,000 yen to 50,000,000 yen with the full amount transferred to other capital surplus. If stock acquisition rights are exercised, the reduction amount will be adjusted by the amount of capital increase from such exercise. The extraordinary general meeting of shareholders is scheduled for February 10, 2027. There will be no change in the total number of issued shares and no impact on shareholders' ownership ratios.

Importance:
Page Updated: November 20, 2026
IR Disclosure Date: November 20, 2026

Key Figures

  • Capital: 335,654,000 yen → 50,000,000 yen
  • Reduction amount: 285,654,000 yen
  • Extraordinary general meeting scheduled date: 2027-02-10

AI要約

Overview of Capital Policy

This matter concerns a plan to implement a gratuitous capital reduction, contingent on approval of the “Reduction of Capital” item at the extraordinary general meeting of shareholders, to reduce capital from 335,654,000 yen to 50,000,000 yen and transfer the entire amount to other capital surplus. If stock acquisition rights are exercised, the company will reduce capital in an amount that, together with the increase in capital resulting from such exercise, equals the planned reduction amount. There will be no change in the total number of issued shares and no impact on shareholders’ ownership ratios. The schedule for the reduction is: Board resolution date November 20, 2026; shareholders’ meeting resolution date February 10, 2027 (scheduled); final date for creditors to raise objections March 24, 2027; effective date March 26, 2027 (scheduled).

Outlook and Impact

The company explains that the implementation of this matter will not affect the total number of issued shares or net assets, and will have no direct impact on the Group’s results for the fiscal year ending March 2027. The above is subject to approval at the extraordinary general meeting of shareholders.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

OncoTherapy Science, Inc.

Company overview · Stock price · Financial data · All IR

View company page →